Alex Eggermont
MD, PhD
Professor of Immuno-oncology
👥Biography 个人简介
Alex Eggermont pioneered adjuvant immunotherapy for resected high-risk melanoma, leading EORTC 18071 (ipilimumab) and KEYNOTE-054 (pembrolizumab) which established adjuvant checkpoint inhibitors as standard of care. His decades of EORTC leadership shaped European melanoma clinical research. He continues to investigate predictive biomarkers and treatment duration.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Alex Eggermont 的研究动态
Follow Alex Eggermont's research updates
留下邮箱，当我们发布与 Alex Eggermont（University Medical Center Utrecht and Princess Maxima Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment